Pfizer's Resurgence in the RSV Vaccine Market: Reclaiming Ground and Intensifying Global Competition

After temporarily losing out to GSK in the race for an RSV vaccine with Pfizer choosing not to stand still, the company has instead regrouped and is preparing to launch another assault on the market. In the vaccine industry, there is nothing more powerful than winning a big contract in the home country of a competitor. Recently, the UK government made an important decision to choose Pfizer to supply 5 million doses of RSV vaccine over the next two years. This decision not only showcased Pfizer's strength but also added a new luster to its standing in the global vaccine market.

The UK government's choice was no accident. Earlier this month, the news was posted on the UK government's "Find a Tender" website, explicitly stating that the specific value of the contract had been temporarily withheld "to avoid harming the legitimate commercial interests of suppliers." This approach not only demonstrated the UK government's rigor and fairness in the procurement process but also won valuable market trust for Pfizer.

As the official launch of the UK's RSV immunization program on Monday morning, patients are beginning to learn how to receive the Abrysvo vaccine. The UK government has stated that the vaccine is expected to be officially launched in early August, providing strong protection for patients. Meanwhile, Pfizer is also actively preparing to ensure that the vaccine can be supplied to the UK market on time and in the required quantities.

Looking back, GSK's performance in the vaccine field has always been highly regarded. Last May, the company became the first pharmaceutical company to receive FDA approval for the Arexvy injection, which was a major victory for the US company. Four weeks later, Pfizer followed suit and also received FDA approval. However, GSK's lead advantage allowed it to take a key advantage in the commercialization process, according to reports, Arexvy's sales reached 1.238 billion pounds (about $1.5 billion) last year, while Abrysvo's sales were $890 million. Although Pfizer's sales were slightly lower, its strength in vaccine research and marketing should not be underestimated.

It is worth noting that Pfizer made significant progress in the fourth quarter of last year. Abrysvo's sales increased from $375 million to $515 million in a row, a growth trend that was impressive. In August of this year, the FDA approved Abrysvo for pregnant women to receive the vaccine, which further boosted Abrysvo's sales. This progress not only showcased Pfizer's strength in vaccine research, but also added a new card to its global vaccine market competition. Meanwhile, competitor GSK's Arexvy vaccine is also expanding its market application range. Before the FDA expanded the use of Arexvy to adults aged 50 and older earlier this month, the vaccine was only approved for adults aged 60 and older. This decision further expanded the market potential of Arexvy, but also put more pressure on Pfizer's Abrysvo vaccine.

In addition to GSK and Pfizer, other pharmaceutical companies are also fiercely competing in the RSV vaccine market. In July last year, the Beyfortus vaccine developed by Sanofi and AstraZeneca received the green light approval and can be used to protect infants under 24 months. The appearance of this vaccine has brought new choices to the RSV vaccine market and provided more protection options for patients.

In terms of price, Pfizer's Abrysvo vaccine and GSK's Arexvy vaccine are both competitive. In the US market, Pfizer listed the wholesale cost of Abrysvo at $295 per dose, while GSK listed the wholesale cost of Arexvy at $280 per dose. The performance of the two vaccines is also quite similar. In the first year, the effectiveness of Arexvy in preventing serious diseases was 94%, while the trial results of Abrysvo were 89%. This data shows that both Pfizer's Abrysvo and GSK's Arexvy can play an important role in preventing RSV infections. In summary, although Pfizer has suffered a temporary setback in its competition with GSK's RSV vaccine, it has not given up. By reorganizing its efforts, preparing actively, and continuously innovating, Pfizer is expected to win a larger market share and gain more trust from patients in the future. Meanwhile, as more pharmaceutical companies enter the RSV vaccine market to compete, this market is also expected to see more intense competition and more opportunities for innovation.